GBM Research Reagents: EGFR, IDH1, MGMT & Emerging Immunotherapy Targets

Glioblastoma (GBM, WHO grade 4) is the most aggressive primary brain tumor, with a median survival of 14–16 months despite maximal treatment. The blood-brain barrier (BBB), immunosuppressive TME, and molecular heterogeneity make GBM one of the most challenging cancers for drug development. For a broader view of all oncology reagent categories, see our Cancer Research Reagents hub.

Key Targets and Biomarkers

IDH1 R132H mutation is the most common IDH mutation in gliomas (~70% of grade 2–3 gliomas; rare in primary GBM). Anti-IDH1 R132H antibody (clone H09) provides mutation-specific IHC staining and is integral to the WHO 2021 CNS tumor classification. For diagnostic panel guidance, see our IHC Panel Design guide.

EGFR amplification occurs in ~60% of primary GBM, with the EGFRvIII variant (constitutively active, exons 2–7 deleted) found in ~30% of EGFR-amplified cases. EGFRvIII is tumor-specific (absent in normal tissue), making it an attractive vaccine and CAR-T target. Anti-EGFRvIII-specific antibodies distinguish this variant from wild-type EGFR.

GFAP (glial fibrillary acidic protein) is the standard astrocytic lineage marker. Anti-GFAP antibodies are essential for IHC diagnosis of astrocytic tumors and for monitoring glial differentiation in tumor models.

MGMT promoter methylation predicts benefit from temozolomide chemotherapy. While MGMT status is typically assessed by methylation-specific PCR, anti-MGMT antibodies provide complementary IHC data on protein expression levels.

Emerging GBM immunotherapy targets include: B7-H3 (CD276), IL-13Rα2, and EphA2 — all under investigation as CAR-T targets. VHH nanobodies are of particular interest for GBM because their small size facilitates BBB crossing. Anti-VEGF (bevacizumab) has been used in recurrent GBM, and PD-1 checkpoint blockade trials are ongoing.

References

1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi: 10.1038/nrc3239

3. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550. doi: 10.1038/s41591-018-0014-x

All products are for research use only. For technical support, contact order@abinscience.com.